The U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) have purchased an additional 100 million doses of COVID-19 vaccines
January 29, 2021 2:45pm EST Study has the potential to facilitate a filing for Emergency Use Authorization (EUA) SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 / / Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
Share this article
SCOTTSDALE, Ariz., Feb. 3, 2021 /PRNewswire/ Matrix Medical Network
® (Matrix) today announced a collaboration with global biopharmaceutical company AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca s long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19. Matrix Clinical Solutions will meet eligible volunteers where they live and work with a fleet of Mobile Health Clinics and skilled clinicians, with a focus on populations more impacted by COVID-19.
Matrix Medical Network Mobile Health Clinic
Matrix is supporting the Phase III clinical trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis in approximately 1,125 participants in the US and UK. Participants in this trial will include adults over 18 years of age following exposure to SARS-COV-2 and who are therefore at appreciable risk of developing COVID-19. The trial will include people liv
DOD experts explain: The science behind the COVID-19 vaccines > Air Education and Training Command > Article Display af.mil - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from af.mil Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ellume Announces $231.8 Million Agreement with the U.S. Government to Scale Up Production of .
Ellume HealthFebruary 1, 2021 GMT
The contract includes the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. Government’s pandemic response
The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed;
The investment extends Ellume’s engagement with the U.S. government following the NIH RADx announcement last year; The Ellume COVID-19 Home Test is the first non-prescription over-the-counter self-test authorized by the U.S. Food and Drug Administration